Withdrawal of Alpha Blocker Therapy Following Initial Combination Therapy with 5 Alpha-Reductase Inhibitor (5ARI) Dutasteride for Benign Prostatic Hyperplasia: A Randomised Controlled Trial on Efficacy

被引：0
|
作者：
Ho, C. C. K. Ho [1 ]
Krishna, K. [1 ]
Zulkifli, M. Z. [1 ]
机构：
[1] Univ Kebangsaan Malaysia, Med Ctr, Kuala Lumpur, Malaysia
来源：
BJU INTERNATIONAL | 2013年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P95
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [1] Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
    Barkin, J
    Guimaraes, M
    Jacobi, G
    Pushkar, D
    Taylor, S
    van Vierssen Trip, OB
    EUROPEAN UROLOGY, 2003, 44 (04) : 461 - 466
  • [2] Early Symptom Improvement and Discontinuation of 5-α-Reductase Inhibitor (5ARI) Therapy in Patients With Benign Prostatic Hyperplasia (BPH)
    Kruep, Eric J.
    Phillips, Emily
    Hogue, Susan
    Eaddy, Michael
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (03) : 343 - 348
  • [3] Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
    Eisen, Christoph
    Lulic, Zrinka
    Manuel Palacios-Moreno, Juan
    Adalig, Burkay
    Hennig, Michael
    Cortes, Vanessa
    Gilg, Florian
    Kostev, Karel
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (01) : 37 - 49
  • [4] Editorial comment on "Dutasteride, a 5 alpha-reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia"
    Tanaka, Tomoaki
    Minami, Akinori
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (02) : 157 - 157
  • [5] Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
    Kim, Jae Heon
    Baek, Min Jung
    Sun, Hwa Yeon
    Lee, Bora
    Li, Shufeng
    Khandwala, Yash
    Del Giudice, Francesco
    Chung, Benjamin, I
    PLOS ONE, 2018, 13 (10):
  • [6] Combination of α-blocker and 5 α-reductase Inhibitor for treatment of benign prostatic hyperplasia
    Kang, Deying
    Hu, Caoyang
    Fu, Yanyan
    Wang, Dongwen
    CLINICAL AND INVESTIGATIVE MEDICINE, 2017, 40 (05): : E200 - E210
  • [7] A combination of dutasteride, a 5α-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist for the treatment of symptomatic benign prostatic hyperplasia
    不详
    FORMULARY, 2010, 45 (09) : 272 - 272
  • [8] Effects of 5α-reductase inhibitor therapy with dutasteride on bone metabolism in patients with benign prostatic hyperplasia
    Halis, Fikret
    Oguz, Ural
    Cimen, Haci Ibrahim
    Atik, Yavuz Tarik
    Baydilli, Numan
    Gokce, Ahmet
    KUWAIT MEDICAL JOURNAL, 2021, 53 (02): : 162 - 166
  • [9] Effects of 5α-reductase inhibitor therapy with dutasteride on sexual function in patients with benign prostatic hyperplasia
    Halis, Fikret
    Kumsar, Sukru
    Cimen, Haci Ibrahim
    Gokce, Ahmet
    KUWAIT MEDICAL JOURNAL, 2019, 51 (02): : 140 - 144
  • [10] Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature
    Busetto, Gian Maria
    Del Giudice, Francesco
    D'Agostino, Daniele
    Romagnoli, Daniele
    Minervini, Andrea
    Rocco, Bernardo
    Antonelli, Alessandro
    Celia, Antonio
    Schiavina, Riccardo
    Cindolo, Luca
    Chung, Benjamin, I
    Kim, Jae Heon
    Maggi, Martina
    Sciarra, Alessandro
    De Berardinis, Ettore
    Porreca, Angelo
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2019, 91 (04) : 205 - 211
12345